Last reviewed · How we verify
PACMx5
PACMx5 is a personalized neoantigen vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.
PACMx5 is a personalized neoantigen vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations. Used for Pancreatic cancer (in combination with chemotherapy and immunotherapy).
At a glance
| Generic name | PACMx5 |
|---|---|
| Also known as | Lansoprazole: Prevacid |
| Sponsor | SWOG Cancer Research Network |
| Drug class | Personalized neoantigen vaccine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PACMx5 is an individualized therapeutic cancer vaccine that combines personalized neoantigen identification with checkpoint inhibitor therapy. The vaccine is engineered based on each patient's unique tumor mutations to generate a targeted immune response against cancer cells. It is being evaluated in combination with standard chemotherapy and immunotherapy in phase 3 trials.
Approved indications
- Pancreatic cancer (in combination with chemotherapy and immunotherapy)
Common side effects
- Injection site reactions
- Fatigue
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PACMx5 CI brief — competitive landscape report
- PACMx5 updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI